Early View

Original research article

PAP telehealth models and long-term therapy termination: a healthcare database analysis

Holger Woehrle, Christoph Schoebel, Joachim H. Ficker, Andrea Graml, Jürgen Schnepf, Ingo Fietze, Peter Young, Michael Arzt


This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2024. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
PAP telehealth models and long-term therapy termination: a healthcare database analysis

Holger Woehrle¹, Christoph Schoebel², Joachim H. Ficker³, Andrea Graml⁴, Jürgen Schnepf⁴, Ingo Fietze⁵, Peter Young⁶, Michael Arzt⁷

¹Sleep and Ventilation Center Blaubeuren, Lung Center Ulm, Ulm, Germany
²Department of Sleep Medicine, University Duisburg-Essen, Essen, Germany
³Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuernberg and Paracelsus Medical University, Nuernberg, Germany
⁴ResMed Science Center, ResMed Germany, Martinsried, Germany
⁵Centre for Sleep Medicine, CCM-CC11, Charité-Universitätsmedizin Berlin, Berlin, Germany
⁶Department for Neurology, Medical Park, Bad Feilnbach, Germany
⁷Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany

Correspondence to: Holger Woehrle, Sleep and Ventilation Center Blaubeuren/Lung Center Ulm, Olgastr. 83, 89073 Ulm, Germany. Tel: +49 731 967940; Fax: +49 731 9679413; Email: hwoehrle@lungenzentrum-ulm.de

Take-home message

PAP therapy termination rates are lowest when telemonitoring-guided proactive care is combined with a patient engagement tool; this approach could ensure achievement of the long-term benefits associated with effective sleep apnoea treatment
ABSTRACT

Telemonitoring-guided interventions can improve short-term positive airway pressure (PAP) therapy adherence, but long-term effects are unknown. This study investigated long-term PAP therapy termination in patients with sleep apnoea managed with standard care, telemonitoring-guided proactive care, or telemonitoring-guided proactive care + patient engagement tool.

German healthcare provider data were analysed retrospectively. Individuals aged 18–100 years who started PAP from 2014–2019 and had device type/interface data were included. Time-to-termination periods were analysed using Kaplan-Meier plots and Cox proportional hazards regression, adjusted for age, sex, insurance type, and device and mask type.

The per-protocol population (valid telemonitoring data) included 104,612 individuals (71% male; 95% aged >40 years). Mean follow-up was 3.3±2.0 years. The overall therapy termination rate was significantly lower in the telemonitoring-guided proactive care group versus standard care (20% vs 27%; p<0.001), and even lower in the telemonitoring-guided care + patient engagement tool group (11%; p<0.001 vs other treatment groups). Adjusted risk of therapy termination was lower versus standard care (hazard ratio [95% confidence interval]: 0.76 [0.74–0.78] and 0.41 [0.38–0.44] for telemonitoring-guided proactive care alone and + patient engagement). Age <50 or >59 years and use of a nasal pillows or full-face mask were significant predictors of therapy termination; male sex, use of telemonitoring-guided proactive care (± patient engagement), and private insurance were significantly associated with lower therapy termination rates.

Use of telemonitoring-guided proactive care and a patient engagement tool was associated with lower rates of PAP therapy termination.
**Key words:** positive airway pressure; adherence; therapy termination; patient engagement; telemonitoring; sleep-disordered breathing; obstructive sleep apnea
Introduction

Continuous positive airway pressure (CPAP) is the standard therapy for obstructive sleep apnoea (OSA) [1]. Adherence to positive airway pressure (PAP) therapy is essential for its beneficial effects and for maximising the magnitude of these benefits [2-4]. However, suboptimal adherence is a challenging problem when CPAP is used in clinical practice, and limits the potential effectiveness of PAP therapy in daily patient care [5].

Telemedicine strategies represent a more recent approach to improving device usage and the management of PAP therapy in patients with sleep apnoea. Data from some prospective intervention trials have shown improvements in device usage and therapy adherence with a variety of telemedicine strategies compared with standard care [6-9], but this was not the case in some other studies [10,11]. Nevertheless, the currently available body of evidence from randomised, prospective, observational and retrospective analyses suggests a beneficial role for telemonitoring in improving usage of PAP therapy and decreasing healthcare professional workload (Table 1) [6-16], although these data are highly heterogeneous in terms of factors such as patient population, interventions investigated and outcome parameters. When data from 33 published studies enrolling a total of 8,689 participants were combined in a systematic review and meta-analysis, use of telemedicine strategies for the management of follow-up in individuals with OSA had a beneficial effect on compliance and was more cost effective than standard care [17].

The availability of cloud-connected devices and the opportunity afforded by big data analysis provides the opportunity to evaluate the effects of different telemonitoring strategies on PAP device usage and therapy termination (as the most extreme form of nonadherence) in patients managed using current technology. In this context, we were able to demonstrate that telemonitoring-guided proactive care can reduce PAP therapy termination rates within the first year of treatment [16], and that the addition of a patient engagement tool can improve
device usage in the first 180 days after PAP initiation [15]. However, there is hardly any published evidence relating to PAP therapy termination rates over the longer term in patients managed using different telehealth-based care strategies. Therefore, this big data analysis was designed to investigate long-term rates of therapy termination in patients with sleep apnoea treated with PAP therapy and managed using standard care, telemonitoring-guided proactive care, or telemonitoring-guided proactive care plus a patient engagement tool. The aim was to determine which of these approaches was most effective for facilitating the long-term continuation of PAP therapy usage.

**Methods**

**Study design**

This retrospective non-interventional study used data from a German healthcare provider (ResMed Healthcare). Part of the registration process for AirView™ included the provision of patient consent to allow the use of their anonymised PAP data to be used for research purposes. European Union medical data protection regulation (MDPR) allows for the use of strictly anonymised data for scientific purposes. In this study all individual patient data analysed were anonymised to comply with these regulations, and therefore specific ethics approval was not required for this study.

**Study participants**

Patients aged ≥18 years who had an indication for PAP therapy (moderate-to-severe sleep apnoea, or mild sleep apnoea with significant symptoms), started PAP therapy between 2014 and 2019, had data on the type of device and interface (mask) used, and had an observation time of >0 days (indicating start of therapy) were included (Figure 1). PAP therapy for all patients was initiated in Germany, where national guidelines [18] provide detailed
recommendations regarding the initiation and follow-up of therapy. This includes initiation of PAP therapy during attended polysomnography, and early outpatient follow-up visit within 6 weeks after the start of treatment and then annual follow-up. Individuals using adaptive servo-ventilation or bilevel PAP therapy were excluded.

**Interventions**

Three patient groups were defined based on management approaches chosen/accepted by patients during their routine clinical management: those receiving standard care; those receiving telemonitoring-guided proactive care (AirView™; ResMed); and those managed using telemonitoring-guided proactive care and a patient engagement tool (myAir™; ResMed).

**Standard care**

Standard care was defined as normal clinical follow-up care by the treating physician based on German guidelines [18]. These suggest that polygraphy follow-up should be performed within 6 months of therapy initiation, plus clinical visits as required; these are often annually and include download of device data.

**Telemonitoring-guided proactive care**

The remote telemonitoring system (AirView™) connected wirelessly with the PAP devices. AirView™ is a Health Insurance Portability and Accountability Act-compliant, password-protected cloud-based technology. PAP device data are transferred automatically to AirView™ on a daily basis to help clinicians remotely manage PAP therapy and compliance. As per homecare provider standard operating procedures, if data showed that PAP usage during the first 2 weeks of therapy was <4 h/day, the homecare provider contacted the patient
by telephone (if authorised by the treating institution). From 2 weeks onwards, patients were notified by telephone or letter if telemonitoring data showed that PAP device usage had decreased significantly and/or fell below 4 h/night. Patients were contacted by telephone and provided with detailed information about their PAP usage and provided with strategies to overcome therapy-related issues, such as upper airway dryness, pressure and mask leak.

Patient engagement tool

The patient engagement tool provides patients with real-time feedback and coaching based on their data within AirView™. Patients sign themselves up for myAir™ and the platform is accessed via logging in to the myAir™ website. Interactions with the patient include: a myAir™ score, usage-based praise messages, usage-based exception messages, exception-based leak, exception-based AHI, and “badges.” The daily myAir™ score is determined based on device usage hours, mask seal (as an indicator of leak), events per hour, and number of times for mask on/off. Personalised coaching/reinforcement messages are sent via e-mail and are designed to increase self-management skills, recognise success, and identify and resolve simple treatment issues. The messages provide general tips on how to make PAP therapy more comfortable or messages of encouragement when patients meet a certain milestone (e.g., average usage of >4 h/night).

Data extraction and definitions

A de-identified copy of all available information was provided to the physicians and statistician who performed the data analysis, similar to previous studies [14,15]. Data extracted from the database for each patient included patient age and sex, type of PAP device (automatically-titrating CPAP [APAP] or CPAP), type of insurance (public or private), and mask type (nasal, nasal pillows or full-face), therapy start date, and date of therapy
termination (but not device usage hours). Additional information, such as sleep apnoea severity and comorbidities, were not available from this healthcare provider database (which contains less information than a full electronic medical record).

**Outcomes**

The key outcome of interest was the rate of therapy termination over at least 3 years of follow-up from initiation of PAP therapy. Therapy termination could take place at any time from the therapy start date and was defined as return of the PAP device to the healthcare provider. Reason for therapy termination had to be patient factors or physician decision; therapy termination for other reasons (e.g. healthcare system factors) was not evaluated. Participants were followed for at least 3 years after the initiation of PAP therapy, but therapy discontinuation could occur at any time from the time of initiation onwards.

**Statistical analysis**

All patients who met the inclusion criteria were included in the intention-to-treat (ITT) population. The per-protocol (PP) population included patients from the ITT population who had telemonitoring data, which would be equivalent to populations undergoing telemonitoring in clinical practice. All analyses were undertaken in both the ITT and PP populations; data from the PP population are reported because these reflect real-world clinical practice.

Numerical data are presented as mean ± standard deviation (SD). Between-group differences were analysed using a t-test because the large sample size allows for approximation with normal distribution. Ordinal and nominal data were presented as absolute and relative frequency. Time-to-termination data were analysed using Kaplan-Meier plots and Cox proportional hazards regression, with adjustment for potential confounders (including age,
Results

Study population

From an initial potential sample of 108,470 patients who started PAP therapy between 2014 and 2019, were aged between 18 and 100 years and had first mask and first device data available, the PP population included 104,612 patients receiving APAP or CPAP (71% male, mean age 61±13 years) (Figure 1, Table 2). Differences between the different patient groups were numerically small, but some did reach statistical significance (likely due to the large sample size) (Table 2). The proportion of patients managed with each strategy changed over time, with increasing numbers utilising connected technologies at later dates of therapy initiation (Figure 2). Mean follow-up was 3.3±2.0 years.

Therapy termination rates

The overall therapy termination rate was slightly but significantly lower in the telemonitoring-guided proactive care group compared with standard care (27% vs 20%; p<0.001]) and lower again in the telemonitoring-guided proactive care + patient engagement tool group (11%; p<0.001 vs. standard care and telemonitoring-base proactive care groups) (Table 3). Overall, therapy termination was most likely in the first two years after PAP initiation (Figure S1). Unadjusted Cox proportional hazard analysis showed that telemonitoring-guided proactive care reduced the risk of therapy termination compared with standard care (hazard ratio [95% confidence interval] values of 0.79 [0.77–0.82] for telemonitoring-guided proactive care and 0.39 [0.37–0.42] for telemonitoring-guided
proactive care + patient engagement tool) (Figure 3). In a Cox proportional hazard analysis adjusted for age, sex, insurance type, device type and mask type, hazard ratio (95% confidence interval) values for therapy termination versus standard care were 0.76 [0.74–0.78] for telemonitoring-guided proactive care and 0.41 [0.38–0.44] for telemonitoring-guided proactive care + patient engagement tool (Figure 3).

**Predictors of therapy termination**

Significant predictors of therapy termination were age <50 years and age >60 years (reference: age 50–60 years), and use of a nasal pillows or full-face mask (reference: nasal mask). In contrast, male versus female sex and having private versus public insurance were significantly associated with lower rates of therapy termination (Figure 4). Similar patterns were seen in the standard care (Figure S2A) and telemonitoring-guided proactive care (Figure S2B) groups, but findings in the telemonitoring-guided proactive care + patient engagement tool group were more variable (Figure S2C), probably due to the smaller number of patients in this group.

**Discussion**

The results of this analysis show that a telemonitoring-guided proactive care strategy, alone or in combination with a patient engagement tool, was associated with a sustained reduction in rates of PAP therapy termination over time, and that this reduction was greatest in patients managed using both telemonitoring-guided proactive care and a patient engagement tool. Results were consistent in the ITT and PP analyses, but the magnitude of effect was greater in the PP population, which is more representative of patients managed with telemonitoring-guided proactive care in clinical practice. This is the first time that three different approaches to PAP therapy management have been compared, and our study is one of the very few
currently published studies to investigate longer-term usage of PAP therapy using modern healthcare delivery models.

Lack of adherence is not directly comparable with therapy termination because some non-adherent patients may still have their devices (and therefore have the potential to use them) whereas those who terminated their therapy have returned their PAP devices. Therapy termination is thus the most extreme form of non-adherence. Despite this, our data showed that there is the potential to prevent therapy termination in the majority of patients with the use of telemonitoring-guided proactive care, and especially telemonitoring-guided proactive care plus a patient engagement tool.

In a previous long-term study analysis data from the Scottish National Sleep Centre, the proportion of patients who had stopped PAP therapy after 5 years was 32% [19]. In the current study, overall therapy termination rates in the intervention groups were much lower than this (21% for telemonitoring-guided proactive care and 11% for telemonitoring-guided proactive care + patient engagement tool), and the standard care group had a similar therapy termination rate (26%). A Swiss cohort study showed a gradual decline in adherence over time, which is consistent with the trajectories of the therapy termination curves in our study. The fact that the Scottish and Swiss studies [8,19] were conducted over earlier time periods is one potential explanation for the lower rates of long-term device usage compared with our analysis. It is possible that established therapeutic advances, different patient populations, and differences in standard care between countries have contributed to the lower rates of therapy discontinuation in our study compared with earlier data. Certainly, the use of newer technologies such as telemonitoring-guided proactive care and a patient engagement tool appeared to improve PAP device usage even over longer-term follow-up in our study.

The Kaplan-Meier and Cox proportional hazards curves in the current study showed a gradual decline in PAP usage over time, and further separation between the curves for the
three different groups as follow-up time increased. This could indicate a continuing influence of the telemonitoring and telemonitoring + proactive care management strategies on treatment termination rates. We also suggest that the nature of the curves over time indicates that baseline differences between the three study groups or selection bias may not have had a marked influence on the findings because if these factors were the most important factors determining therapy termination, the curves would diverge early and run parallel during the remaining follow-up period.

In line with a previous study by our group [14], we found a U-shaped relationship between age and treatment discontinuation, with significantly higher rates of therapy termination in younger and older age groups compared to those aged 50–60 years. It is possible that the reasons underlying therapy termination could differ between age groups, but this information was not captured in the current analysis. However, older age may be associated with less adoption of the digital technologies that support adherence to PAP therapy, increasing the likelihood of therapy termination in older age groups. Also similar to the previous publication, we found higher therapy termination rates in among publicly insured patients versus privately insured patients. This may be due to better support for privately insured individuals, for whom the number of support visits is not capped, or may reflect different socioeconomic status or proactive health behaviours of privately versus publicly insured individuals. However, these suggestions are speculation only. Nevertheless, our results confirm the relevance of age and type of insurance as predictors of both short- and medium-to long-term drop-out rates after PAP prescription. Our data showing higher rates of therapy termination in females in this German analysis are consistent with an analysis of a large French dataset [20]. The finding that use of a nasal pillows or full-face mask was associated with a higher rate of therapy termination could be because these types of interface may be
more likely to be used in individuals who are considered to be at greater risk of having interface issues during PAP therapy, but this is an area for future investigation.

Overall adherence to CPAP in randomised clinical trials has barely improved over the period 1994 to 2015 [21]. However, our results suggest that newer telemedicine strategies with proactive patient care have the potential to markedly increase the proportion of patients who remain on PAP therapy over the medium term.

A recent meta-analysis also confirmed that telemedicine strategies are in general associated with improved short-term adherence to PAP therapy in OSA patients, showing a clinically relevant increase in device use of more than 0.5 hours per night [22]. The authors did note that it is still unclear which specific telemedicine intervention can be most effectively implemented in clinical practice [22]. The big data analysis presented herewith uses data from routine clinical practice and showed that two specific telemedicine strategies were associated with a reductions in long-term treatment termination rate in patients receiving PAP therapy.

The main strengths of this study are the large dataset collected during routine clinical practice and the analysis of PAP therapy termination over a 6-year period. However, there are also some limitations that need to be considered when interpreting our results. This is a retrospective analysis using a database created for administrative rather than scientific purposes. This means that data on potentially important variables such as the method used to diagnose sleep apnoea, the severity of sleep apnoea, the presence of daytime sleepiness and comorbidities, and therapy parameters such as pressures or use of heated humidification are missing. ResMed Healthcare is one of the largest healthcare providers of PAP devices in Germany, and choice of healthcare provider is made by patients and physicians. Given the size of the sample, this should be representative of the wider German population of PAP users. However, generalisability of the findings to other populations in Germany, and those
from other regions should be done with caution. The three groups examined in our study were formed by individual decisions of each patient and their physician (i.e. self-selected) rather than in a prospective randomised manner. This selection bias means that our results could have been influenced by a variety of confounding variables. However, the persistent way in which the treatment termination curves diverge over time is an indicator of a probable real effect of the different management strategies studied. During the recruitment phase, the number of patients who opted for the telemonitoring-guided proactive care and patient engagement options increased steadily. This most likely reflects increases in the availability of these tools and awareness of their potential benefits over time. However, this also means that the proportion of patients managed using the combination strategy (i.e. telemonitoring-guided proactive care with the patient engagement tool) was comparatively low in the overall study population (approximately 9%). Accordingly, larger, preferably randomised, studies are needed to confirm our results. Based on the trends described above, it should be easier to include a higher proportion of patients with the patient engagement tool in such a new study. Finally, this study focused only on two distinct groups – those who terminated therapy and returned their device and those who continued using PAP therapy. There is no data on patients who did not terminate therapy but had low device usage, because PAP device usage hours were not available for the standard care group and were not accessible for the other groups due to data protection requirements. This would be an interesting area of research for future studies. Nevertheless, therapy termination is an objective and clinically relevant endpoint that is increasingly being investigated with respect to PAP therapy [20].

In conclusion, use of telemonitoring-guided proactive care was associated with lower PAP therapy termination rates compared with standard care. The addition of a patient engagement was associated with even lower therapy termination rates, and may therefore contribute to prevention of long-term therapy termination. Based on these associations, it is possible that
PAP-treated patients who are managed using telemonitoring-guided proactive care and a patient engagement tool could be more likely to experience the long-term benefits associated with effective sleep apnoea treatment. These data highlight the value of personalised healthcare that provides feedback and interventions tailored to the needs of the individual patient to maintain long-term device usage in patients with PAP therapy.

**Funding**

This study was funded by ResMed Germany.

**Acknowledgements**

Medical writing assistance was provided by Nicola Ryan, independent medical writer, funded by ResMed.

**Author contributions**

HW, CS and MA were involved in the conception, hypotheses delineation, and design of the analysis, the analysis and interpretation of the data information, writing the article and revising the article prior to submission. CS, JHF, JS, IF and PY were substantially involved in the design of the study, acquisition and interpretation of the data, and critical revision of the article prior to submission. AG performed the statistical analysis and helped to draft the manuscript. HW assumes responsibility for the accuracy and completeness of the analyses and for the fidelity of this report to the trial protocol.

**Role of sponsors**
This work represents an academic and industry partnership. The study sponsor hosts the data platform and provided physician investigators with access to the anonymised data. Physicians then analysed the data and prepared the manuscript. All authors had full access to all the data and made the decision to submit for publication.

**Conflict of Interest**

HW has received lecture/consulting fees from Astra Zeneca, Allergopharma, Bioprojet, Boehringer Ingelheim, Chiesi, GSK, Novartis, Inspire, Jazz and ResMed, and research support from ResMed and Novartis. CS has received grants from Astra Zeneca, ResMed and Bayer, consulting fees from ResMed, Idorsia, Bristol-Myers Squibb and Astra Zeneca, and honoraria/lecture fees from Berlin Chemie, Takeda and Mementor; he also has unpaid roles as treasurer of the German Sleep Society, head of the Telemedicine Working Group of the German Society for Internal Medicine, and treasurer of the Sleep Apnea Working Group of the German Cardiac Society. JF has received grants and personal/lecture fees from ResMed and Inspire. AG and JS are employees of ResMed. IF reports support and grants from ResMed and Löwenstein Medical, personal fees from ResMed and Bioprojet, and has an unpaid role as director of the German Sleep Foundation. PY reports personal fees from Sanofi Genzyme, Biomarin, UCB Pharma, Medice, ResMed, Löwenstein Medical and Vanda, and grants from Lowensteinstiftung and the German Ministry of Education and Science (BMBF). MA has received grant support from ResMed, the ResMed Foundation, Philips Respironics and the Else-Kroehner Fresenius Foundation, and lecture and/or consulting fees from ResMed, WITA Italia, and Philips Respironics.
References


**Figure Legends**

**Figure 1.** Study flow chart. PAP = positive airway pressure therapy.

**Figure 2.** Proportion of patients managed using different strategies over time. Standard = standard care; TM = telemonitoring-guided proactive care; TM + PE = telemonitoring-guided proactive care + patient engagement tool.

**Figure 3.** Cumulative positive airway pressure therapy terminations over time (per-protocol population) based on Kaplan-Meier analysis are shown as unadjusted Cox regression plots (A) and Cox regression plots adjusted for age, sex, insurance type, device type and mask type (B). Shadows either side of each line show the 95% confidence intervals. TM = telemonitoring.

**Figure 4.** Forest plots of Cox regression analyses of potential predictors of positive airway pressure therapy termination in the per-protocol population over the full follow-up period (showing adjusted hazard ratio [HR] and 95% confidence interval [CI] values).
Tables

Table 1. Summary of data from studies investigating the effects of telemonitoring on adherence to positive airway pressure therapy

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Patients (n)</th>
<th>Design (duration)</th>
<th>Comparators</th>
<th>Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prospective/randomized trials</td>
<td>OSAS (n=250) Age 48–63 y 82% male</td>
<td>Randomized (12 months)</td>
<td>TM vs standard care</td>
<td>Median observed CPAP usage at 12 months was 2.98 h/night in the TM group versus 0.99 h/night in the standard care group (p=0.006); corresponding adherence rates were 44.7% and 34.5%.</td>
</tr>
<tr>
<td>Sparrow et al, 2010 [9]</td>
<td>Moderate-to-severe OSA (n=75) Mean age 53.5±11.2 y 80% male</td>
<td>Randomized (3 months)</td>
<td>TM vs standard care</td>
<td>Mean 3-month PAP usage was 191 min/day in the TM group versus 105 min/day in the standard care group (between-group difference 87 min/day, 95% CI 25–148; p=0.006) On days when PAP was used, usage was 321 min in the TM group and 207 min in the standard care group (difference 113 min, 95% CI 62–164; p=0.0001. Significant independent predictors of adherence were use of TM, age and baseline ESS score.</td>
</tr>
<tr>
<td>Fox et al, 2012 [6]</td>
<td>OSA (n=51) Mean age 54 y 82% male</td>
<td>Randomized (4 weeks)</td>
<td>TM vs standard clinical care or weekly phone call</td>
<td>Average APAP usage in the first 4 weeks of therapy was 5.0±1.8 h/night in the TM group, 5.1±2.5 h/night in the standard care group and 3.9±2.6 h/night in the phone call group; corresponding residual AHI values were 5.3±3.0/h, 5.0±2.5/h and 5.6±3.8/h.</td>
</tr>
<tr>
<td>Abreu et al, 2013 [10]</td>
<td>Newly diagnosed OSA (n=293) Age 45–64 y 74% male</td>
<td>Prospective (30 days)</td>
<td>TM vs standard care</td>
<td>Patients in the TM vs standard care group used PAP for longer (5.2 vs 4.6 min/night; p=0.05) and on more nights (28 vs 26; p&lt;0.001). TM use remained associated with adherence after adjustment for age and the proportion of outpatients in each group (p=0.02).</td>
</tr>
<tr>
<td>Study</td>
<td>Condition</td>
<td>Design</td>
<td>Type</td>
<td>Comparison</td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>--------</td>
<td>------</td>
<td>------------</td>
</tr>
<tr>
<td>Munafo et al, 2016 [11]</td>
<td>Newly diagnosed OSA (n=122) Mean age 51 y 69% male</td>
<td>Prospective (90 days)</td>
<td>TM vs standard care</td>
<td>Adherence rates (83% vs 73%), CPAP usage (5.1±1.9 h/day vs 4.7±2.1 h/day), residual AHI (3.0±4.1/h vs 2.8±3.8/h) and change in ESS score (−5.8±5.5 vs −5.1±5.9) did not differ significantly between the TM and standard care groups. The number of minutes of coaching required per pt was 59% lower in the TM versus standard care group (23.9±26.0 vs 58.3±25.0; p&lt;0.0001).</td>
</tr>
<tr>
<td>Hwang et al, 2018 [7]</td>
<td>New PAP users (n=1,455) Mean age 49.1±12.5 y 49% male</td>
<td>Randomized, open-label (90 days)</td>
<td>TM-based education (Tel-Ed) vs CPAP TM with automated feedback messaging (Tel-TM) vs both strategies (Tel-both) vs usual care (UC)</td>
<td>Average CPAP usage at 90 days was 3.8±2.5, 4.0±2.4, 4.4±2.2, and 4.8±2.3 h/day in the UC, Tel-Ed, Tel-TM, and Tel-both groups. Usage was significantly higher in the Tel-TM and Tel-both groups versus usual care (both p=0.0002) but not in the Tel-Ed group (p=0.10). Medicare adherence rates were 53.5, 61.0, 65.6, and 73.2% in the UC, Tel-Ed, Tel-TM, and Tel-both groups (Tel-both vs. UC, p=0.001; Tel-TM vs. UC, p=0.003; Tel-Ed vs. UC, p=0.07), respectively.</td>
</tr>
<tr>
<td>Coma-del-Corral et al, 2013 [12]</td>
<td>Suspected OSAS (n=40) Mean age 53±10.3 y 63% male</td>
<td>Observational (6 months)</td>
<td>TM vs standard care</td>
<td>The 6-month CPAP compliance rate was 75% for pts evaluated with a teleconsultation and 85% for those evaluated in the clinic. The real cost of TM was estimated to be similar to, or lower than, that of conventional PSG.</td>
</tr>
<tr>
<td>Woehrle et al, 2017 [16]</td>
<td>New PAP users (n=6802) Mean age 59±13 y 75% male</td>
<td>Observational (1 year)</td>
<td>TM vs standard care</td>
<td>PAP therapy termination rate was significantly lower (5.4% vs 11.0%; p&lt;0.001) and time to therapy termination was significantly longer (348±58 vs 337±76 days; p&lt;0.05) in the TM versus standard care group. Cox proportional hazard analysis showed that the risk of PAP termination was significantly reduced in the TM versus standard care group (HR 0.48, 95% CI 0.4–0.57); findings were consistent in pt subgroups by sex, PAP device type and insurance status, and in pts aged ≥40 y.</td>
</tr>
<tr>
<td>Malhotra et al, 2018 [13]</td>
<td>New PAP users (n=128,037) Mean age 52 y</td>
<td>Retrospective (90 days)</td>
<td>TM alone vs TM + pt engagement tool</td>
<td>The proportion of pts who achieved US Medicare adherence criteria was 87.3% in the TM + pt engagement group vs. 70.4% in the TM group (p&lt;0.0001). Corresponding values for average device usage were 5.9 vs. 4.9 h/night (p&lt;0.0001).</td>
</tr>
<tr>
<td>Woehrle et al, 2018 [15]</td>
<td>Indication for PAP (n=1000)</td>
<td>Retrospective, big data analysis (180 days)</td>
<td>TM alone vs TM + pt engagement tool</td>
<td>The proportion of nights with device usage ≥4 h was 77±25% in the TM + pt engagement group versus 63±32% in the TM group (p&lt;0.001). Therapy termination occurred less often in the TM + pt engagement group (p&lt;0.001). The AHI was similar in the two groups, but leak was significantly lower in the TM + pt engagement versus TM group (2.7±4.0 vs 4.1±5.3 L/min; p&lt;0.001).</td>
</tr>
</tbody>
</table>

AHI, apnoea-hypopnoea index; APAP, automatically titrating continuous positive airway pressure; ASV, adaptive servo-ventilation; CI, confidence interval; ESS, Epworth Sleepiness Scale; FU, follow-up; HR, hazard ratio; OSA, obstructive sleep apnoea; OSAS, obstructive sleep apnoea syndrome; PAP, positive airway pressure; PSG, polysomnography; pts, patients; TM, telemonitoring; y, years.
<table>
<thead>
<tr>
<th></th>
<th>Overall (n=104,612)</th>
<th>Mode of care</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Standard care (n=45,927)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>30,008 (29)</td>
<td>13,732 (30)</td>
</tr>
<tr>
<td>Age, years</td>
<td>61 ± 13</td>
<td>61 ± 13</td>
</tr>
<tr>
<td>Private health insurance, n (%)</td>
<td>16,516 (16)</td>
<td>8,364 (18)</td>
</tr>
<tr>
<td>Mask type, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal</td>
<td>52,386 (50)</td>
<td>21,512 (47)</td>
</tr>
<tr>
<td>Nasal pillows</td>
<td>15,135 (14)</td>
<td>6,981 (15)</td>
</tr>
<tr>
<td>Full-face</td>
<td>37,091 (35)</td>
<td>17,434 (38)</td>
</tr>
</tbody>
</table>

*p<0.016 vs standard care; †p<0.016 vs telemonitoring.
<table>
<thead>
<tr>
<th></th>
<th>Overall (n=104,612)</th>
<th>Standard care (n=45,927)</th>
<th>Telemonitoring-guided proactive care (n=49,360)</th>
<th>Telemonitoring-guided proactive care + patient engagement tool (n=9,325)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation period, years</td>
<td>3.3 ± 2.0</td>
<td>3.3 ± 2.1</td>
<td>3.4 ± 1.9*</td>
<td>3.2 ± 1.4*†</td>
</tr>
<tr>
<td>Therapy termination, n (%)</td>
<td>23,255 (22)</td>
<td>12,592 (27)</td>
<td>9,676 (20)*</td>
<td>987 (11)*†</td>
</tr>
<tr>
<td>Therapy termination in the first year, n (%)</td>
<td>11,071 (11)</td>
<td>6,328 (14)</td>
<td>4,339 (9)*</td>
<td>404 (4)*†</td>
</tr>
<tr>
<td>Therapy termination rate per 100 patient-years</td>
<td>6.6</td>
<td>7.6</td>
<td>6.2</td>
<td>3.3</td>
</tr>
</tbody>
</table>

*p<0.016 vs standard care; †p<0.016 vs telemonitoring.
Figure 1

Started PAP therapy between 2014 and 2019 (n=138,531)

Incomplete dataset (n=27,413)
- Age not 18–100 years (n=2,778)
- Device unknown (n=9,719)
- Mask unknown (n=17,760)

Complete dataset (n=108,470)

Observation time <1 day (n=160)

Intention-to-treat population (n=108,310)

Agreed to telomonitoring but no data sent (n=3,696)

Per-protocol population (n=104,612)
Figure 2
Figure 3
<table>
<thead>
<tr>
<th>Variable</th>
<th>HR [CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>0.80 [0.77; 0.82]</td>
</tr>
<tr>
<td>Male</td>
<td>Reference</td>
</tr>
<tr>
<td>Age &lt;30 years</td>
<td>1.74 [1.53; 1.96]</td>
</tr>
<tr>
<td>Age 30 to &lt;40 years</td>
<td>1.30 [1.22; 1.39]</td>
</tr>
<tr>
<td>Age 40 to &lt;50 years</td>
<td>1.12 [1.07; 1.17]</td>
</tr>
<tr>
<td>Age 50 to &lt;60 years</td>
<td>Reference</td>
</tr>
<tr>
<td>Age 60 to &lt;70 years</td>
<td>1.09 [1.05; 1.13]</td>
</tr>
<tr>
<td>Age 70 to &lt;80 years</td>
<td>1.33 [1.28; 1.38]</td>
</tr>
<tr>
<td>Age ≥ 80 years</td>
<td>1.81 [1.73; 1.90]</td>
</tr>
<tr>
<td>Public insurance</td>
<td>Reference</td>
</tr>
<tr>
<td>Private insurance</td>
<td>0.65 [0.63; 0.68]</td>
</tr>
<tr>
<td>Nasal mask</td>
<td>Reference</td>
</tr>
<tr>
<td>Nasal pillows mask</td>
<td>1.18 [1.14; 1.23]</td>
</tr>
<tr>
<td>Full face mask</td>
<td>1.22 [1.18; 1.25]</td>
</tr>
</tbody>
</table>

Figure 4
ONLINE SUPPLEMENT

PAP telehealth models and long-term therapy termination: a healthcare database analysis

Holger Woehrle¹, Christoph Schoebel², Joachim H. Ficker³, Andrea Graml⁴, Jürgen Schnepf⁴, Ingo Fietze⁵, Peter Young⁶, Michael Arzt⁷

¹Sleep and Ventilation Center Blaubeuren, Lung Center Ulm, Ulm, Germany
²Department of Sleep Medicine, University Duisburg-Essen, Essen, Germany
³Department of Respiratory Medicine, Allergology and Sleep Medicine, General Hospital Nuernberg and Paracelsus Medical University, Nuernberg, Germany
⁴ResMed Science Center, ResMed Germany, Martinsried, Germany
⁵Centre for Sleep Medicine, CCM-CC11, Charité-Universitätsmedizin Berlin, Berlin, Germany
⁶Department for Neurology, Medical Park, Bad Feilnbach, Germany
⁷Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany
Figure S1. Timing of positive airway pressure therapy termination during follow-up
Figure S2. Forest plots of Cox regression analyses of potential predictors of positive airway pressure therapy termination in the per-protocol population (A. standard care group; B. telemonitoring-guided proactive care group; C. telemonitoring-guided proactive care + patient engagement tool group) over the full follow-up period (showing adjusted hazard ratio [HR] and 95% confidence interval [CI] values).
<table>
<thead>
<tr>
<th>Variable</th>
<th>HR [CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>0.73 [0.63; 0.84]</td>
</tr>
<tr>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>Age &lt;30 years</td>
<td>2.05 [1.27; 3.30]</td>
</tr>
<tr>
<td>Age 30 to &lt;40 years</td>
<td>1.36 [1.05; 1.76]</td>
</tr>
<tr>
<td>Age 40 to &lt;50 years</td>
<td>1.08 [0.88; 1.32]</td>
</tr>
<tr>
<td>Age 50 to &lt;60 years</td>
<td>Reference</td>
</tr>
<tr>
<td>Age 60 to &lt;70 years</td>
<td>1.39 [1.17; 1.65]</td>
</tr>
<tr>
<td>Age 70 to &lt;80 years</td>
<td>1.67 [1.53; 2.29]</td>
</tr>
<tr>
<td>Age ≥ 80 years</td>
<td>4.28 [3.30; 5.56]</td>
</tr>
<tr>
<td>Public insurance</td>
<td>Reference</td>
</tr>
<tr>
<td>Private insurance</td>
<td>0.45 [0.37; 0.55]</td>
</tr>
<tr>
<td>Nasal mask</td>
<td>Reference</td>
</tr>
<tr>
<td>Nasal pillows mask</td>
<td>1.12 [0.93; 1.34]</td>
</tr>
<tr>
<td>Full face mask</td>
<td>1.24 [1.08; 1.43]</td>
</tr>
</tbody>
</table>